Clinical and epidemiological characteristics and effectiveness of antiviral therapy for COVID-19 in children: The experience of the first year of the pandemic

Background. The use of antiviral agents can shorten the duration of the viral infection.
The aim: to study the clinical and epidemiological features and the effectiveness of antiviral therapy for new coronavirus infection (COVID-19) in outpatient children.
Materials and methods. From April 2020 to March 2021, 9334 outpatient children aged from 0 months to 17 years were randomly tested for new coronavirus infection. SARS-CoV-2 RNA was detected in oropharyngeal and nasal material by PCR. Patients with confirmed new coronavirus infection were prescribed interferon-alpha (IFN-α) intranasally, antiviral agents of systemic action. The control group consisted of children with COVID-19 who did not receive treatment.
Results. When examining clinically healthy contact children, SARS-CoV-2 RNA was detected in 7.4 % of cases. In the structure of ARI, the specific weight of COVID-19 was 12.3 % with the peak incidence in April-May (up to 22.8 %) and NovemberDecember (up to 30.0 %). In half of the cases, children became infected in the family, and usually adults were the index patient. In 47.7 % of cases, an asymptomatic form of COVID-19 was registered without significant differences in patients of different ages. In one third of children with concomitant pathology, the disease was asymptomatic, in half it was mild, in other cases moderate severity was diagnosed. The clinical picture of COVID-19 did not differ from other ARIs. Anosmia (9.4 %) in half of the cases was combined with ageusia (4.4 %) and was significantly more common in boys. The duration of clinical manifestations in children of the control group and those who received antiviral therapy did not statistically significantly differ in mild and severity of the disease. Also, various antiviral therapy options did not significantly affect the duration of SARS-CoV-2 detection in children with various forms of COVID-19.
Conclusion. In the first year of the pandemic, the novel coronavirus infection did not dominate the pattern of respiratory diseases in outpatient children. Further research is required to develop pediatric guidelines for the treatment of COVID-19 at the outpatient stage.

1. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020; 382(24): 2302-2315. doi: 10.1056/NEJMoa2006100

2. Rosenberg ES, Dufort EM, Blog DS, Hall EW, Hoefer D, Backenson BP, et al. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State-March 2020. Clin Infect Dis. 2020; 71(8): 1953-1959. doi: 10.1093/cid/ciaa549

3. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. Nature. 2020; 584(7821): 425-429. doi: 10.1038/s41586-020-2488-1

4. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020; 323(23): 2427-2429. doi: 10.1001/jama.2020.8707

5. Steinman JB, Lum FM, Ho P.P-K, Kaminski N, Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proc Natl Acad Sci U S A. 2020; 117(40): 24620-24626. doi: 10.1073/pnas.2012358117

6. Nickbakhsh S, Mair C, Matthews L, Reeve R, Johnson P, Thorburn F, et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci U S A. 2019; 116(52): 27142-27150. doi: 10.1073/pnas.1911083116

7. Timchenko VN, Sukhovetskaya VF, Chernova TM, Barakina EV, Pochinyaeva LM, Malinovskaya VV, et al. The role of early etiological decoding of acute respiratory viral infections in antiviral therapy choice for children in a hospital setting. Pediatria. 2020; 99(1): 101-106. (In Russ.)

8. Mateus J, Grifoni A, Tark A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020; 370(6512): 89-94. doi: 10.1126/science.abd3871

9. Felsensteina S, Hedrich ChM. COVID-19 in children and young people. Lancet Rheumatol. 2020; 2(9): 514-516. doi: 10.1016/S2665-9913(20)30212-5

10. Fialkowski A, Gernez Ya, Arya P, Weinacht KG, Kinane TB, Yonker LM. Insight into the pediatric and adult dichotomy of COVID‐19: Age‐related differences in the immune response to SARS‐CoV‐2 infection. Pediatr Pulmonol. 2020; 55(10): 2556-2564. doi: 10.1002/ppul.24981

11. Deville JaG, Song Eu, Ouellette ChP. COVID-19: Clinical manifestations and diagnosis in children. UpToDate. URL: https://www.uptodate.com/contents/covid-19-clinical-manifestationsand-diagnosis-in-children [date of access: 25.06.2021].

12. Lee В, Raszka WV. COVID-19 transmission and children: The child is not to blame. Pediatrics. 2020; 146(2): 2020004879. doi: 10.1542/peds.2020-004879

13. Zachariah Ph, Halabi KC, Johnson CL, Whitter S, Sepulveda J, Green DA. Symptomatic infants have higher nasopharyngeal SARS-CoV-2 viral loads but less severe disease than older children. Clin Infect Dis. 2020; 71(16): 2305-2306. doi: 10.1093/cid/ciaa608

14. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA. 2003; 290(24): 3222-3228. doi: 10.1001/jama.290.24.3222

15. Salman AA, Waheed MH, Ali-Αbdulsahib AA, Atwan ZW. Low type I interferon response in COVID-19 patients: Interferon response may be a potential treatment for COVID-19. Biomed Rep. 2021; 14(5): 43. doi: 10.3892/br.2021.1419

16. Wang N, Zhan Ya, Zhu L, Hou Zh, Liu F. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020; 28(3): 455-464.e2. doi: 10.1016/j.chom.2020.07.005

17. Avdeev SN, Adamyan LV, Alekseeva EI, Bagnenko SF, Baranov AA, Baranova NN, et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Interim Guidelines – Version 11 (05/07/2021). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/BМР_COVID-19.pdf [date of access: 25.06.2021]. (In Russ.)

18. Hao Sh, Yan R, Zhang Sh, Lian J, Cai H, Lian J, et al. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: A preliminary matched case-control study. J Zhejiang Univ Sci B. 2020; 21(8): 628-636. doi: 10.1631/jzus.B2000211

19. Dokhov MA, Tikhomirova AA, Vaulin GF. Nonparametric criteria in the program “Statistica”. Saint Petersburg: SPbGPMU; 2019. (In Russ.).

20. Ivanov DO, Chernova TM, Pavlova EB, Timchenko VN, Barakina EV. Coronavirus infection. Pediatr (Sankt-Peterburg). 2020; 11(3): 109-117. (In Russ.). doi: 10.17816/PED113109-117

21. Timchenko VN, Sukhovetskaya VF, Chernova TM, Kaplina TA, Subbotina MD, Bulina OV, et al. Results of 5-year monitoring of the circulation of seasonal coronaviruses in hospitalized children in the pre-pandemic period. Children Infections. 2021; 20(1): 5-11. (In Russ.). doi: 10.22627/2072-8107-2021-20-1-5-11

22. Shakmaeva MA, Chernova TM, Timchenko VN, Nachinkina TA, Tetyushin KV, Kaplina TA, et al. Features of the new coronavirus infection in children of different ages. Children Infections.

23. 2021; 20(2): 5-9. (In Russ.). doi: 10.22627/2072-8107-2021-20-2-5-9

24. Snape MD, Viner RM. COVID-19 in children and young people. Science. 2020; 370(6514): 286-288. doi: 10.1126/science. abd6165

25. Patel А, Charani Е, Ariyanayagam D, Abdulaal А, Denny SJ, Mughal N, et al. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. Clin Microbiol Infect. 2020; 26(9): 1236-1241. doi: 10.1016/j.cmi.2020.05.026

26. Venturini E, Montagnani C, Garazzino S, Donà D, Pierantoni L, Vecchio AL, et al. Treatment of children with COVID-19: Position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediatr. 2020; 46(1): 139. doi: 10.1186/s13052-020-00900-w

27. Gulick RM, Lane HC, Masur H, Pau AK, Aberg Ju, Adimora A, et al. Coronavirus disease 2019 (COVID-19) treatment guidelines/special considerations in children. National Institutes of Health. April 21, 2021. URL: https://www.covid19treatmentguidelines.nih.gov/special-populations/children/z [access date: 25.06.2021].